U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H22FN3O6
Molecular Weight 359.3501
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CAPECITABINE

SMILES

CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]2O[C@H](C)[C@@H](O)[C@H]2O

InChI

InChIKey=GAGWJHPBXLXJQN-UORFTKCHSA-N
InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1

HIDE SMILES / InChI

Molecular Formula C15H22FN3O6
Molecular Weight 359.3501
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/xeloda-drug.htm https://www.drugs.com/mtm/capecitabine.html

Capecitabine is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered systemic prodrug which is converted to 5-fluorouracil (5-FU). Both normal and tumor cells metabolize 5-FU to 5-fluoro-2’-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2’-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis. Most common adverse reactions (≥30%) were diarrhea, hand-and-foot syndrome, nausea, vomiting, abdominal pain, fatigue/weakness, and hyperbilirubinemia. The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.

CNS Activity

Curator's Comment: The CNS penetration of 5-FU (Capecitabine is a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body) in human was predicted based on the penetration in preclinical brain tumor, CSF, and human PK and the predicted free CNS concentration was below the antiproliferative potency.

Originator

Curator's Comment: # Hoffmann-La Roche Inc.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
XELODA

Approved Use

Capecitabine tablets, USP are a nucleoside metabolic inhibitor with antineoplastic activity indicated for: • Adjuvant Colon Cancer (1.1) oPatients with Dukes’ C colon cancer • Metastatic Colorectal Cancer (1.1) oFirst-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred • Metastatic Breast Cancer (1.2) oIn combination with docetaxel after failure of prior anthracycline-containing therapy oAs monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen 1.1 Colorectal Cancer •Capecitabine tablets, USP are indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. Capecitabine was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent capecitabine in the adjuvant treatment of Dukes’ C colon cancer. •Capecitabine tablets are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with capecitabine monotherapy. Use of capecitabine instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. 1.2 Breast Cancer •Capecitabine tablets, USP in combination with docetaxel are indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. •Capecitabine tablets monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated (e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents). Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen.

Launch Date

8.9389439E11
Primary
XELODA

Approved Use

Capecitabine tablets, USP are a nucleoside metabolic inhibitor with antineoplastic activity indicated for: • Adjuvant Colon Cancer (1.1) oPatients with Dukes’ C colon cancer • Metastatic Colorectal Cancer (1.1) oFirst-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred • Metastatic Breast Cancer (1.2) oIn combination with docetaxel after failure of prior anthracycline-containing therapy oAs monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen 1.1 Colorectal Cancer •Capecitabine tablets, USP are indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. Capecitabine was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent capecitabine in the adjuvant treatment of Dukes’ C colon cancer. •Capecitabine tablets are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with capecitabine monotherapy. Use of capecitabine instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. 1.2 Breast Cancer •Capecitabine tablets, USP in combination with docetaxel are indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. •Capecitabine tablets monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated (e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents). Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen.

Launch Date

8.9389439E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3515 ng/mL
1250 mg/m² 2 times / day multiple, oral
dose: 1250 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
.ALPHA.-FLUORO-.BETA.-ALANINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
9105 ng/mL
1000 mg/m² 2 times / day multiple, oral
dose: 1000 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CAPECITABINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
45027 ng × h/mL
1250 mg/m² 2 times / day multiple, oral
dose: 1250 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
.ALPHA.-FLUORO-.BETA.-ALANINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
10238 ng × h/mL
1000 mg/m² 2 times / day multiple, oral
dose: 1000 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CAPECITABINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.78 h
1000 mg/m² 2 times / day multiple, oral
dose: 1000 mg/m²
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CAPECITABINE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
65%
CAPECITABINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2500 mg 2 times / day multiple, oral
Highest studied dose
Dose: 2500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2500 mg, 2 times / day
Sources: Page: p.1799
unhealthy, 34-68
n = 7
Health Status: unhealthy
Condition: Breast cancer
Age Group: 34-68
Sex: F
Population Size: 7
Sources: Page: p.1799
DLT: Hand-and-foot syndrome, Diarrhea...
Dose limiting toxicities:
Hand-and-foot syndrome (grade 3, 28.6%)
Diarrhea (grade 3, 14.29%)
Sources: Page: p.1799
2000 mg 2 times / day multiple, oral
MTD
Dose: 2000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 2 times / day
Sources: Page: p.1799
unhealthy, 41-53
n = 7
Health Status: unhealthy
Condition: Breast cancer
Age Group: 41-53
Sex: F
Population Size: 7
Sources: Page: p.1799
DLT: Hand-and-foot syndrome...
Dose limiting toxicities:
Hand-and-foot syndrome (grade 3, 14.29%)
Sources: Page: p.1799
1250 mg/m2 2 times / day multiple, oral
Recommended
Dose: 1250 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 1250 mg/m2, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Adjuv ant Colon Cancer|Metastatic Colorectal Cancer|Metastatic Breast Cancer
Sources: Page: p.1
Disc. AE: Coagulopathy, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Coagulopathy
Diarrhea
Cardiotoxicity
Dehydration
Renal failure
Fetal damage
Mucocutaneous disorder (severe)
Stevens Johnson syndrome
Toxic epidermal necrolysis
Hyperbilirubinemia
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Diarrhea grade 3, 14.29%
DLT
2500 mg 2 times / day multiple, oral
Highest studied dose
Dose: 2500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2500 mg, 2 times / day
Sources: Page: p.1799
unhealthy, 34-68
n = 7
Health Status: unhealthy
Condition: Breast cancer
Age Group: 34-68
Sex: F
Population Size: 7
Sources: Page: p.1799
Hand-and-foot syndrome grade 3, 28.6%
DLT
2500 mg 2 times / day multiple, oral
Highest studied dose
Dose: 2500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2500 mg, 2 times / day
Sources: Page: p.1799
unhealthy, 34-68
n = 7
Health Status: unhealthy
Condition: Breast cancer
Age Group: 34-68
Sex: F
Population Size: 7
Sources: Page: p.1799
Hand-and-foot syndrome grade 3, 14.29%
DLT
2000 mg 2 times / day multiple, oral
MTD
Dose: 2000 mg, 2 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 2 times / day
Sources: Page: p.1799
unhealthy, 41-53
n = 7
Health Status: unhealthy
Condition: Breast cancer
Age Group: 41-53
Sex: F
Population Size: 7
Sources: Page: p.1799
Cardiotoxicity Disc. AE
1250 mg/m2 2 times / day multiple, oral
Recommended
Dose: 1250 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 1250 mg/m2, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Adjuv ant Colon Cancer|Metastatic Colorectal Cancer|Metastatic Breast Cancer
Sources: Page: p.1
Coagulopathy Disc. AE
1250 mg/m2 2 times / day multiple, oral
Recommended
Dose: 1250 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 1250 mg/m2, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Adjuv ant Colon Cancer|Metastatic Colorectal Cancer|Metastatic Breast Cancer
Sources: Page: p.1
Dehydration Disc. AE
1250 mg/m2 2 times / day multiple, oral
Recommended
Dose: 1250 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 1250 mg/m2, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Adjuv ant Colon Cancer|Metastatic Colorectal Cancer|Metastatic Breast Cancer
Sources: Page: p.1
Diarrhea Disc. AE
1250 mg/m2 2 times / day multiple, oral
Recommended
Dose: 1250 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 1250 mg/m2, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Adjuv ant Colon Cancer|Metastatic Colorectal Cancer|Metastatic Breast Cancer
Sources: Page: p.1
Fetal damage Disc. AE
1250 mg/m2 2 times / day multiple, oral
Recommended
Dose: 1250 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 1250 mg/m2, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Adjuv ant Colon Cancer|Metastatic Colorectal Cancer|Metastatic Breast Cancer
Sources: Page: p.1
Hyperbilirubinemia Disc. AE
1250 mg/m2 2 times / day multiple, oral
Recommended
Dose: 1250 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 1250 mg/m2, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Adjuv ant Colon Cancer|Metastatic Colorectal Cancer|Metastatic Breast Cancer
Sources: Page: p.1
Renal failure Disc. AE
1250 mg/m2 2 times / day multiple, oral
Recommended
Dose: 1250 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 1250 mg/m2, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Adjuv ant Colon Cancer|Metastatic Colorectal Cancer|Metastatic Breast Cancer
Sources: Page: p.1
Stevens Johnson syndrome Disc. AE
1250 mg/m2 2 times / day multiple, oral
Recommended
Dose: 1250 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 1250 mg/m2, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Adjuv ant Colon Cancer|Metastatic Colorectal Cancer|Metastatic Breast Cancer
Sources: Page: p.1
Toxic epidermal necrolysis Disc. AE
1250 mg/m2 2 times / day multiple, oral
Recommended
Dose: 1250 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 1250 mg/m2, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Adjuv ant Colon Cancer|Metastatic Colorectal Cancer|Metastatic Breast Cancer
Sources: Page: p.1
Mucocutaneous disorder severe
Disc. AE
1250 mg/m2 2 times / day multiple, oral
Recommended
Dose: 1250 mg/m2, 2 times / day
Route: oral
Route: multiple
Dose: 1250 mg/m2, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Adjuv ant Colon Cancer|Metastatic Colorectal Cancer|Metastatic Breast Cancer
Sources: Page: p.1
PubMed

PubMed

TitleDatePubMed
The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
1999
Vision of the future: capecitabine.
2001
Optimizing the use of irinotecan in colorectal cancer.
2001
[The potential of capecitabine (Xeloda) in the treatment of disseminated solid tumors].
2001
Clinical pharmacokinetics of capecitabine.
2001
The Twenty-third Annual San Antonio Breast Cancer Symposium.
2001
Metastatic breast cancer: understanding current management options.
2001 Apr
[Coronary insufficiency after an oral intake of capecitabine].
2001 Aug-Sep
Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.
2001 Dec
5-fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer.
2001 Feb
Oral fluoropyrimidine-based combination therapy in gastrointestinal cancer.
2001 Jan
Clinical status of capecitabine in the treatment of breast cancer.
2001 Jan
Capecitabine (Xeloda).
2001 Jan-Feb
Capecitabine monotherapy in metastatic colorectal cancer.
2001 Jul
New chemotherapy approaches in colorectal cancer.
2001 Jul
[Tumoral levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in elderly colorectal cancer patients].
2001 Jun
Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug.
2001 Jun
Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer.
2001 Jun 1
[Oral cytostatic drug in colorectal carcinoma. Selective tumor therapy at home].
2001 Mar 29
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
2001 Nov 1
Clinical picture: leopard-like vitiligo with capecitabine.
2001 Nov 10
[Recent aspects of palliative treatment of metastasized colorectal carcinoma].
2001 Sep 15
Prediction of the response of colorectal cancer to systemic therapy.
2002 Feb
Clinical experience of capecitabine in metastatic breast cancer.
2002 Feb
An evolving role for oral fluoropyrimidine drugs.
2002 Feb 15
Taxanes and capecitabine in combination: rationale and clinical results.
2002 Jan
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
2002 Jan
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
2002 Jan 15
Xeloda. Warning: drug interaction increase bleeding risks.
2002 Mar
Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.
2008 Jan
Patents

Sample Use Guides

Take XELODA with water within 30 min after a meal. Monotherapy: 1250 mg/m2 twice daily orally for 2 weeks followed by a one week rest period in 3-week cycles.
Route of Administration: Oral
After 48 hours treatment of MCF7 cell line with capecitabine, in the concentration of 1147.9 μg/ml 50% of cells have been inhibited. After 72 hours treatment of the cells with capecitabine, at the concentration of 921 μg/ml 50% of cells have been inhibited.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:33:56 UTC 2023
Edited
by admin
on Fri Dec 15 15:33:56 UTC 2023
Record UNII
6804DJ8Z9U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CAPECITABINE
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
XELIRI COMPONENT CAPECITIBINE
Common Name English
CAPECITABINE [VANDF]
Common Name English
RO-091978000
Code English
Capecitabine [WHO-DD]
Common Name English
CAPECITABINE [USP MONOGRAPH]
Common Name English
CAPECITABINE [JAN]
Common Name English
Xelox component capecitabine
Common Name English
CAPECYTABINE
Common Name English
ECANSYA
Brand Name English
PENTYL 1-(5-DEOXY-.BETA.-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINECARBAMATE
Common Name English
CARBAMIC ACID, (1-(5-DEOXY-.BETA.-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINYL)-, PENTYL ESTER
Common Name English
CAPECITABINE SUN
Brand Name English
CAPECITABINE [USP-RS]
Common Name English
NSC-759853
Code English
CAPECITABINE [USP IMPURITY]
Common Name English
CAPECITABINE [EP MONOGRAPH]
Common Name English
RO-09-1978000
Code English
CAPECITABINE [MI]
Common Name English
CAPECITABINE [MART.]
Common Name English
CAPECITABINE ACCORD
Brand Name English
CAPECITABINE [EMA EPAR]
Common Name English
CAPIIBINE
Common Name English
capecitabine [INN]
Common Name English
XELODA
Brand Name English
RO 09-1978/000
Code English
CAPECITABINE TEVA
Brand Name English
CAPECITABINE MEDAC
Brand Name English
CAPECITABINE [USAN]
Common Name English
CAPECITABINE [ORANGE BOOK]
Common Name English
CAPTABIN
Common Name English
CAPECITABINE [HSDB]
Common Name English
CAPECITIBINE
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS CAPECITABINE ACCORD (AUTHORIZED: COLONIC NEOPLASMS, BREAST NEOPLASMS, COLORECTAL NEOPLASMS, STOMACH NEOPLASMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
EMA ASSESSMENT REPORTS CAPECITABINE MEDAC (AUTHORIZED: COLORECTAL NEOPLASMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
EMA ASSESSMENT REPORTS CAPECITABINE ACCORD (AUTHORIZED: STOMACH NEOPLASMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
EMA ASSESSMENT REPORTS CAPECITABINE SUN (AUTHORIZED: STOMACH NEOPLASMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
EMA ASSESSMENT REPORTS CAPECITABINE SUN (AUTHORIZED: COLONIC NEOPLASMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
EMA ASSESSMENT REPORTS ECANSYA (AUTHORIZED: COLONIC NEOPLASMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
EMA ASSESSMENT REPORTS ECANSYA (AUTHORIZED: COLORECTAL NEOPLASMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
NDF-RT N0000000233
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
EMA ASSESSMENT REPORTS XELODA (AUTHRIZED: STOMACH NEOPLASMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
EMA ASSESSMENT REPORTS CAPECITABINE TEVA (AUTHORIZED: COLONIC NEOPLASMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
EMA ASSESSMENT REPORTS XELODA (AUTHORIZED: COLORECTAL NEOPLASMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
EMA ASSESSMENT REPORTS CAPECITABINE TEVA (AUTHORIZED: COLORECTAL NEOPLASMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
NCI_THESAURUS C1557
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
WHO-VATC QL01BC06
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
EMA ASSESSMENT REPORTS CAPECITABINE TEVA (AUTHORIZED: STOMACH NEOPLASMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
LIVERTOX NBK547986
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
EMA ASSESSMENT REPORTS ECANSYA (AUTHORIZED: STOMACH NEOPLAMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
EMA ASSESSMENT REPORTS CAPECITABINE SUN (AUTHORIZED: COLORECTAL NEOPLASMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
EMA ASSESSMENT REPORTS CAPECITABINE ACCORD (AUTHORIZED: COLORECTAL NEOPLASMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
NDF-RT N0000175595
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
WHO-ATC L01BC06
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
EMA ASSESSMENT REPORTS XELODA (AUTHORIZED: COLONIC NEOPLASMS)
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
Code System Code Type Description
HSDB
7656
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
ChEMBL
CHEMBL1773
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
EPA CompTox
DTXSID3046451
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
PUBCHEM
60953
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
EVMPD
SUB12474MIG
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
DRUG BANK
DB01101
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
MERCK INDEX
m3027
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY Merck Index
NSC
759853
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
INN
7317
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
RXCUI
194000
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY RxNorm
DAILYMED
6804DJ8Z9U
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
CHEBI
31348
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
DRUG CENTRAL
480
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
SMS_ID
100000089303
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
CAS
154361-50-9
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
NCI_THESAURUS
C1794
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
IUPHAR
6799
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
WIKIPEDIA
CAPECITABINE
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
MESH
C110904
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
RS_ITEM_NUM
1090706
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
LACTMED
Capecitabine
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
USAN
HH-37
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
FDA UNII
6804DJ8Z9U
Created by admin on Fri Dec 15 15:33:56 UTC 2023 , Edited by admin on Fri Dec 15 15:33:56 UTC 2023
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
METABOLITE -> PARENT
by carboxylesterase
METABOLITE -> PARENT
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
BY CYTIDINE DEAMINASE
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
5'-DEOXY-5-FLUORO-N4-(2-METHYL-1-BUTYLOXYCARBONYL)CYTIDINE + 5'-DEOXY-5-FLUORO-N4-(3-METHYL-1-BUTYLOXYCARBONYL)CYTIDINE (NMT-0.5% WEIGHT PERCENT)
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
5'-DEOXY-5-FLUORO-N4-(2-METHYL-1-BUTYLOXYCARBONYL)CYTIDINE + 5'-DEOXY-5-FLUORO-N4-(3-METHYL-1-BUTYLOXYCARBONYL)CYTIDINE (NMT-0.5% WEIGHT PERCENT)
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC